MoonLake Immunotherapeutics
MLTX13.830USD
-0.040-0.29%
收盤 12/26, 16:00（美東）報價延遲15分鐘
881.03M總市值
虧損本益比TTM
關於 MoonLake Immunotherapeutics 公司
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeutics簡介
公司代碼MLTX
公司名稱MoonLake Immunotherapeutics
上市日期Oct 20, 2020
CEOSantos Da Silva (Jorge)
員工數量100
證券類型Ordinary Share
年結日Oct 20
公司地址Dorfstrasse 29
城市ZUG
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Switzerland
郵編6300
電話41415108022
網址https://moonlaketx.com/
公司代碼MLTX
上市日期Oct 20, 2020
CEOSantos Da Silva (Jorge)
MoonLake Immunotherapeutics公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.93M
-6.49%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
2.88M
-6.50%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.93M
-6.49%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
2.88M
-6.50%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月1日 週一
更新時間: 12月1日 週一
持股股東
股東類型
持股股東
持股股東
佔比
BVF Partners L.P.
27.67%
Deep Track Capital LP
6.46%
Santos da Silva (Jorge)
4.31%
Reich (Kristian)
4.15%
Avoro Capital Advisors LLC
2.80%
其他
54.61%
持股股東
持股股東
佔比
BVF Partners L.P.
27.67%
Deep Track Capital LP
6.46%
Santos da Silva (Jorge)
4.31%
Reich (Kristian)
4.15%
Avoro Capital Advisors LLC
2.80%
其他
54.61%
股東類型
持股股東
佔比
Hedge Fund
47.09%
Individual Investor
9.25%
Investment Advisor
6.20%
Investment Advisor/Hedge Fund
5.92%
Research Firm
1.10%
Venture Capital
0.49%
Bank and Trust
0.10%
Pension Fund
0.04%
其他
29.81%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BVF Partners L.P.
19.75M
31.1%
--
--
Jun 30, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
Reich (Kristian)
3.13M
4.93%
+48.98K
+1.59%
Sep 02, 2025
Avoro Capital Advisors LLC
4.15M
6.54%
+1.38M
+49.81%
Jun 30, 2025
Cormorant Asset Management, LP
1.99M
3.14%
-6.50M
-76.52%
Sep 30, 2025
Bodenstedt (Matthias)
616.67K
0.97%
--
--
Mar 15, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.22%
Virtus LifeSci Biotech Clinical Trials ETF
0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
Strive Small-Cap ETF
0.02%
Nuveen ESG Small-Cap ETF
0.02%
iShares Morningstar Small-Cap ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.27%
Global X Guru Index ETF
佔比0.22%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.02%
Strive Small-Cap ETF
佔比0.02%
Nuveen ESG Small-Cap ETF
佔比0.02%
iShares Morningstar Small-Cap ETF
佔比0.01%
John Hancock Multifactor Small Cap ETF
佔比0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
佔比0.01%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
MoonLake Immunotherapeutics的前五大股東是誰？
MoonLake Immunotherapeutics的前五大股東如下：
BVF Partners L.P.持有股份：19.75M佔總股份比例：31.10%。
Santos da Silva (Jorge)持有股份：3.08M佔總股份比例：4.85%。
Reich (Kristian)持有股份：3.13M佔總股份比例：4.93%。
Avoro Capital Advisors LLC持有股份：4.15M佔總股份比例：6.54%。
Cormorant Asset Management, LP持有股份：1.99M佔總股份比例：3.14%。
BVF Partners L.P.持有股份：19.75M佔總股份比例：31.10%。
Santos da Silva (Jorge)持有股份：3.08M佔總股份比例：4.85%。
Reich (Kristian)持有股份：3.13M佔總股份比例：4.93%。
Avoro Capital Advisors LLC持有股份：4.15M佔總股份比例：6.54%。
Cormorant Asset Management, LP持有股份：1.99M佔總股份比例：3.14%。
MoonLake Immunotherapeutics的前三大股東類型是什麼？
MoonLake Immunotherapeutics 的前三大股東類型分別是：
BVF Partners L.P.
Deep Track Capital LP
Santos da Silva (Jorge)
BVF Partners L.P.
Deep Track Capital LP
Santos da Silva (Jorge)
有多少機構持有MoonLake Immunotherapeutics(MLTX)的股份？
截至2025Q3，共有336家機構持有MoonLake Immunotherapeutics的股份，合計持有的股份價值約為52.26M，占公司總股份的73.22% 。與2025Q2相比，機構持股有所增加，增幅為-38.84%。
哪個業務部門對MoonLake Immunotherapeutics的收入貢獻最大？
在--，--業務部門對MoonLake Immunotherapeutics的收入貢獻最大，創收--，占總收入的--% 。
